Colorectal cancer (CRC) is the second leading cause of cancer deaths in the US. Most CRCs either are inherently insensitive to therapeutic treatment or acquire resistance upon relapse. Intrinsic and acquired therapeutic resistance is one of the most significant obstacles in the treatment of CRCs. Mcl-1, a pro-survival Bcl-2 family protein, has recently emerged as a key mediator of therapeutic resistance of CRCs. However, none of the previously described Mcl-1 inhibitors are suitable for clinical development owing to insufficient in vivo efficacy or undesirable pharmacokinetic properties. Utilizing integrated screening approaches and structure-based design, we have recently developed a new class of Mcl-1 inhibitors with novel chemical structures. The lead compound, 483, is highly selective for Mcl-1 and has potent activity against Mcl-1-mediated drug resistance in CRC cells. It also exhibited promising pharmacological properties and completely overcame Mcl-1-mediated drug resistance in vivo. Based on these findings, we propose to test the hypothesis that the 483 class of Mcl-1 inhibitors can be further developed to improve CRC therapy by targeting drug-resistant CRC cells.
Aim 1 : Design and synthesis of novel Mcl-1 inhibitors with improved activity and properties;
Aim 2 : Biophysical, biochemical, structural and functional characterization of novel Mcl-1 inhibitors;
Aim 3 : Determine the efficacy and mechanism of action of novel Mcl-1 inhibitors in CRC cells;
Aim 4. Analyze the pharmacological properties and in vivo efficacy of novel Mcl-1 inhibitors. These studies may provide a major advance towards our long-term goal of developing a novel class of therapy for human cancer by targeting Mcl-1.
Colorectal cancer is one of the leading causes of cancer-related death in the United States. The proposed studies will develop a new class of anticancer agents by targeting a key mediator of drug resistance in colorectal cancer. In the long run, these studies may help improve treatment of colorectal cancer and other types of cancer.
|Wang, Yi-Jun; Fletcher, Rochelle; Yu, Jian et al. (2018) Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis 5:194-203|
|Chen, Dongshi; Tong, Jingshan; Yang, Liheng et al. (2018) PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors. Proc Natl Acad Sci U S A 115:3930-3935|
|Chen, Dongshi; Ni, Hong-Min; Wang, Lei et al. (2018) PUMA induction mediates acetaminophen-induced necrosis and liver injury. Hepatology :|
|Tong, Jingshan; Zheng, Xingnan; Tan, Xiao et al. (2018) Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins. Cancer Res 78:4704-4715|
|Mady, Ahmed S A; Liao, Chenzhong; Bajwa, Naval et al. (2018) Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening. Sci Rep 8:10210|
|Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi et al. (2018) Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene 37:4599-4610|
|Wei, Liang; Leibowitz, Brian J; Epperly, Michael et al. (2018) The GS-nitroxide JP4-039 improves intestinal barrier and stem cell recovery in irradiated mice. Sci Rep 8:2072|
|Fletcher, Rochelle; Wang, Yi-Jun; Schoen, Robert E et al. (2018) Colorectal cancer prevention: Immune modulation taking the stage. Biochim Biophys Acta Rev Cancer 1869:138-148|
|Tong, Jingshan; Tan, Shuai; Nikolovska-Coleska, Zaneta et al. (2017) FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors. Mol Cancer Ther 16:1979-1988|
|Tong, Jingshan; Wang, Peng; Tan, Shuai et al. (2017) Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells. Cancer Res 77:2512-2521|